Aratana Therapeutics Inc
Analyzing Eli Lilly’s Clinical and Business Developments in 1Q16
Elanco, the animal healthcare arm of Eli Lilly, received exclusive and global rights to develop and commercialize Aratana’s (PETX) Gallipart, a drug that treats osteoarthritis in dogs.
IBB’s Top Performers: PETX Gains on Its First FDA Approval
IBB’s top performers for March 21, 2016, were Cara Therapeutics (CARA), OvaScience (OVAS), Sarepta Therapeutics (SRPT), and Aratana Therapeutics (PETX).
IBB Begins the Last Week of 2015 on a Negative Note
The iShares Nasdaq Biotechnology ETF (IBB) fell by 0.75% on December 28, underperforming the broader market.